Affmer proteins are recombinant affinity reagents that exhibit high affinity and high specificity binding across a range of reaction conditions. The rapid in vitro screening process for Affimer binder identification is a flexible system, which allows the directed selection of reagents specific to a wide range of target classes.
Affimer screening can be tailored to both target characteristics and end user applications, while the ease of engineering offers functionalisation of the protein scaffold for use across a number of platforms. Affimer binders to a large number of targets have been successfully developed for a wide range of project requirements.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.